Category Press Releases

Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria

Novartis today announced positive top-line results from the Phase III REMIX-1 and REMIX-2 studies evaluating remibrutinib 25 mg b.i.d., a Bruton’s tyrosine kinase (BTK) inhibitor, in patients with chronic spontaneous…

Read MoreNovartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria

Optum and Capella University Announce New Nurse Practitioner Program To Address the Growing National Need for Skilled Clinicians

Optum, a diversified health services company, and Capella University, an accredited online university, announced a new educational program designed to address the growing need for skilled, advanced practice nurses. The…

Read MoreOptum and Capella University Announce New Nurse Practitioner Program To Address the Growing National Need for Skilled Clinicians